Insiders Buying Greenwich LifeSciences And 2 Other Stocks
Insiders Buying Greenwich LifeSciences And 2 Other Stocks
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades.
儘管週五美國股市收盤大多走低，但仍有一些值得注意的內幕交易。
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
當內部人士購買股票時，這表明他們對公司前景充滿信心，或者他們認爲股票很划算。無論哪種方式，這都預示着做多該股的機會。不應將內幕購買視爲做出投資或交易決策的唯一指標。充其量，它可以爲購買決定提供信心。
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
以下是最近一些值得注意的內幕收購。欲了解更多，請查看 本辛加的內幕交易 平台。
Harrow
耙
- The Trade: Harrow, Inc. (NASDAQ:HROW) 10% owner Opaleye Management Inc. acquired a total of 50,600 shares an average price of $9.65. To acquire these shares, it cost around $488,290.
- What's Happening: On March 19, Harrow reported worse-than-expected fourth-quarter financial results.
- What Harrow Does: Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market.
- 交易：哈羅公司（納斯達克股票代碼：HROW）10％的所有者Opaleye Management Inc. 共收購了50,600股股票 平均價格爲9.65美元。收購這些股票的成本約爲488,290美元。
- 發生了什麼：3月19日，哈羅公佈的第四季度財務業績低於預期。
- 哈羅做什麼：哈羅公司是一家眼部護理製藥公司，致力於爲美國市場發現、開發和商業化眼科藥品。
Greenwich LifeSciences
格林威治生命科學
- The Trade: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO and CFO Snehal Patel acquired a total of 1,500 shares at an average price of $17.68. To acquire these shares, it cost around $26,520.
- What's Happening: On March 12, Greenwich LifeSciences announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain.
- What Greenwich LifeSciences Does: Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
- 交易：格林威治生命科學公司（納斯達克股票代碼：GLSI）首席執行官兼首席財務官斯內哈爾·帕特爾共收購了1,500股股票，平均價格爲17.68美元。收購這些股票的成本約爲26,520美元。
- 發生了什麼：3月12日，格林威治生命科學宣佈與西班牙GEICAM合作啓動歐洲首批臨床研究所。
- 格林威治生命科學公司做什麼：格林威治生命科學公司是一家臨床階段的生物製藥公司，專注於開發GP2，這是一種免疫療法，旨在防止先前接受過手術的患者乳腺癌復發。
Don't forget to check out our premarket coverage here
別忘了在這裏查看我們的上市前報道
BRT Apartments
BRT 公寓
- The Trade: BRT Apartments Corp. (NYSE:BRT) 10% owner Gould Investors L P bought a total of 3,471shares at an average price of $16.26. To acquire these shares, it cost around $56,450.
- What's Happening: On March 12, BRT Apartments posted downbeat quarterly sales.
- What BRT Apartments Does: BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties.
- 交易：BRT Apartments Corp.（紐約證券交易所代碼：BRT）10% 的所有者 Gould Investors L P 共購買了3,471股股票 平均價格爲16.26美元。收購這些股票的成本約爲56,450美元。
- 發生了什麼：3月12日，BRT公寓公佈了悲觀的季度銷售額。
- BRT公寓做什麼：BRT公寓公司是一家房地產投資信託公司。該公司主要專注於多戶住宅物業的所有權、運營和開發。
譯文內容由第三人軟體翻譯。